{"schemaVersion":"2.1","datasetVersion":"2026-07-24.2","generatedAt":"2026-07-24","reviewStatus":"Editorial source review completed; not independently medically reviewed","editorialBoundary":"Educational evidence summaries only. No dosing, sourcing, reconstitution, injection, cycling, stacking, or self-treatment instructions.","citation":"Cite The Peptide Field, the record canonicalPath, dataset version 2026-07-24.2, and every underlying source used for the claim.","reuse":"No additional reuse license is granted by this endpoint. Preserve verdict, scope, evidence basis, review date, and source links together; do not present a record as medical advice or medical review.","changeLogPath":"/corrections#correction-ledger","contactPath":"/corrections","dataset":"sources","count":71,"records":[{"label":"OZEMPIC (semaglutide) prescribing information, revised 05/2026","publisher":"U.S. Food and Drug Administration","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/209637s038lbl.pdf","kind":"Drug label","year":2026,"accessedAt":"2026-07-23","id":"source-ecxlg6","canonicalPath":"/sources#source-ecxlg6","peptides":[{"name":"Semaglutide","slug":"semaglutide"}]},{"label":"RYBELSUS (semaglutide) prescribing information, revised 10/2025","publisher":"U.S. Food and Drug Administration","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/213051s024%2Cs028s029lbl.pdf","kind":"Drug label","year":2025,"accessedAt":"2026-07-23","id":"source-85f4nm","canonicalPath":"/sources#source-85f4nm","peptides":[{"name":"Semaglutide","slug":"semaglutide"}]},{"label":"WEGOVY (semaglutide) prescribing information, revised 03/2026","publisher":"U.S. Food and Drug Administration","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf","kind":"Drug label","year":2026,"accessedAt":"2026-07-23","id":"source-12mxma6","canonicalPath":"/sources#source-12mxma6","peptides":[{"name":"Semaglutide","slug":"semaglutide"}]},{"label":"FDA’s concerns with unapproved GLP-1 drugs used for weight loss","publisher":"U.S. Food and Drug Administration","url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss","kind":"Regulatory","year":2026,"accessedAt":"2026-07-23","id":"source-vaetyb","canonicalPath":"/sources#source-vaetyb","peptides":[{"name":"Semaglutide","slug":"semaglutide"},{"name":"Tirzepatide","slug":"tirzepatide"}]},{"label":"Drug approvals and databases","publisher":"U.S. Food and Drug Administration","url":"https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases","kind":"Regulatory","year":2026,"accessedAt":"2026-07-23","id":"source-11hnb1p","canonicalPath":"/sources#source-11hnb1p","peptides":[{"name":"Semaglutide","slug":"semaglutide"},{"name":"Liraglutide","slug":"liraglutide"},{"name":"Retatrutide","slug":"retatrutide"},{"name":"Abaloparatide","slug":"abaloparatide"}]},{"label":"Insulin: patient and product overview","publisher":"U.S. Food and Drug Administration","url":"https://www.fda.gov/consumers/free-publications-women/insulin","kind":"Regulatory","year":2026,"accessedAt":"2026-07-23","id":"source-140vgft","canonicalPath":"/sources#source-140vgft","peptides":[{"name":"Insulin","slug":"insulin"}]},{"label":"HUMALOG (insulin lispro) prescribing information","publisher":"U.S. Food and Drug Administration","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/020563s214%2C205747s038lbl.pdf","kind":"Drug label","year":2025,"accessedAt":"2026-07-23","id":"source-pt2f9t","canonicalPath":"/sources#source-pt2f9t","peptides":[{"name":"Insulin","slug":"insulin"}]},{"label":"The effect of intensive treatment of diabetes on long-term complications in insulin-dependent diabetes mellitus","publisher":"PubMed · New England Journal of Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/8366922/","kind":"Randomized trial","year":1993,"accessedAt":"2026-07-23","id":"source-1ahh49","canonicalPath":"/sources#source-1ahh49","peptides":[{"name":"Insulin","slug":"insulin"}]},{"label":"Hypoglycemia in the Diabetes Control and Complications Trial","publisher":"PubMed · Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/9000705/","kind":"Randomized trial","year":1997,"accessedAt":"2026-07-23","id":"source-zt78e2","canonicalPath":"/sources#source-zt78e2","peptides":[{"name":"Insulin","slug":"insulin"}]},{"label":"FDA approves the first rapid-acting insulin biosimilar product for diabetes","publisher":"U.S. Food and Drug Administration","url":"https://www.fda.gov/news-events/press-announcements/fda-approves-first-rapid-acting-insulin-biosimilar-product-treatment-diabetes","kind":"Regulatory","year":2026,"accessedAt":"2026-07-23","id":"source-1y575pz","canonicalPath":"/sources#source-1y575pz","peptides":[{"name":"Insulin","slug":"insulin"}]},{"label":"2026 prohibited list","publisher":"World Anti-Doping Agency","url":"https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list","kind":"Anti-doping","year":2026,"accessedAt":"2026-07-23","id":"source-1ygrhgd","canonicalPath":"/sources#source-1ygrhgd","peptides":[{"name":"Insulin","slug":"insulin"},{"name":"BPC-157","slug":"bpc-157"},{"name":"CJC-1295","slug":"cjc-1295"},{"name":"Ipamorelin","slug":"ipamorelin"},{"name":"Tesamorelin","slug":"tesamorelin"},{"name":"Sermorelin","slug":"sermorelin"},{"name":"TB-500","slug":"tb-500"},{"name":"MOTS-c","slug":"mots-c"},{"name":"AOD-9604","slug":"aod-9604"}]},{"label":"MOUNJARO (tirzepatide) prescribing information","publisher":"U.S. Food and Drug Administration","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s009lbl.pdf","kind":"Drug label","year":2026,"accessedAt":"2026-07-23","id":"source-f2qac7","canonicalPath":"/sources#source-f2qac7","peptides":[{"name":"Tirzepatide","slug":"tirzepatide"}]},{"label":"ZEPBOUND (tirzepatide) prescribing information","publisher":"U.S. Food and Drug Administration","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s042lbl.pdf","kind":"Drug label","year":2026,"accessedAt":"2026-07-23","id":"source-lxrna8","canonicalPath":"/sources#source-lxrna8","peptides":[{"name":"Tirzepatide","slug":"tirzepatide"}]},{"label":"Tirzepatide once weekly for the treatment of obesity","publisher":"PubMed · New England Journal of Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35658024/","kind":"Randomized trial","year":2022,"accessedAt":"2026-07-23","id":"source-19a3jo0","canonicalPath":"/sources#source-19a3jo0","peptides":[{"name":"Tirzepatide","slug":"tirzepatide"}]},{"label":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","publisher":"PubMed · New England Journal of Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34170647/","kind":"Randomized trial","year":2021,"accessedAt":"2026-07-23","id":"source-1cmocmt","canonicalPath":"/sources#source-1cmocmt","peptides":[{"name":"Tirzepatide","slug":"tirzepatide"}]},{"label":"July 2026 PCAC briefing on BPC-157-related bulk drug substances","publisher":"U.S. Food and Drug Administration","url":"https://www.fda.gov/media/193343/download","kind":"FDA review","year":2026,"accessedAt":"2026-07-23","id":"source-1gf419u","canonicalPath":"/sources#source-1gf419u","peptides":[{"name":"BPC-157","slug":"bpc-157"}]},{"label":"Certain bulk drug substances for use in compounding that may present significant safety risks","publisher":"U.S. Food and Drug Administration","url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","kind":"Regulatory","year":2026,"accessedAt":"2026-07-23","id":"source-1qr5jd8","canonicalPath":"/sources#source-1qr5jd8","peptides":[{"name":"BPC-157","slug":"bpc-157"},{"name":"CJC-1295","slug":"cjc-1295"},{"name":"Ipamorelin","slug":"ipamorelin"},{"name":"GHK-Cu","slug":"ghk-cu"},{"name":"MOTS-c","slug":"mots-c"},{"name":"AOD-9604","slug":"aod-9604"}]},{"label":"BPC-157 as an investigational peptide therapeutic: translational development barriers","publisher":"PubMed · Pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/42198317/","kind":"Science review","year":2026,"accessedAt":"2026-07-23","id":"source-1w2430m","canonicalPath":"/sources#source-1w2430m","peptides":[{"name":"BPC-157","slug":"bpc-157"}]},{"label":"Safety of intravenous infusion of BPC157 in humans: a pilot study","publisher":"PubMed · Alternative Therapies in Health and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/40131143/","kind":"Human pilot","year":2025,"accessedAt":"2026-07-23","id":"source-18l9rks","canonicalPath":"/sources#source-18l9rks","peptides":[{"name":"BPC-157","slug":"bpc-157"}]},{"label":"Promoting effect of BPC 157 on tendon healing: tendon outgrowth, cell survival, and migration","publisher":"PubMed · Journal of Applied Physiology","url":"https://pubmed.ncbi.nlm.nih.gov/21030672/","kind":"Preclinical","year":2011,"accessedAt":"2026-07-23","id":"source-9irrdo","canonicalPath":"/sources#source-9irrdo","peptides":[{"name":"BPC-157","slug":"bpc-157"}]},{"label":"BPC 157 for acute hamstring muscle strain repair","publisher":"ClinicalTrials.gov","url":"https://clinicaltrials.gov/study/NCT07437547","kind":"Trial registry","year":2026,"accessedAt":"2026-07-23","id":"source-wpj2w1","canonicalPath":"/sources#source-wpj2w1","peptides":[{"name":"BPC-157","slug":"bpc-157"}]},{"label":"Prolonged GH and IGF-1 stimulation by CJC-1295 in healthy adults","publisher":"PubMed · Journal of Clinical Endocrinology & Metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/16352683/","kind":"Randomized trial","year":2006,"accessedAt":"2026-07-23","id":"source-1inf9pj","canonicalPath":"/sources#source-1inf9pj","peptides":[{"name":"CJC-1295","slug":"cjc-1295"}]},{"label":"Pulsatile GH secretion during continuous stimulation by CJC-1295","publisher":"PubMed · Journal of Clinical Endocrinology & Metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/17018654/","kind":"Human pharmacology","year":2006,"accessedAt":"2026-07-23","id":"source-go4m8t","canonicalPath":"/sources#source-go4m8t","peptides":[{"name":"CJC-1295","slug":"cjc-1295"}]},{"label":"CJC-1295 pharmacy compounding advisory review","publisher":"U.S. Food and Drug Administration","url":"https://www.fda.gov/media/183819/download","kind":"FDA review","year":2024,"accessedAt":"2026-07-23","id":"source-1mpvkqp","canonicalPath":"/sources#source-1mpvkqp","peptides":[{"name":"CJC-1295","slug":"cjc-1295"}]},{"label":"Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers","publisher":"PubMed · Pharmaceutical Research","url":"https://pubmed.ncbi.nlm.nih.gov/10496658/","kind":"Human pharmacology","year":1999,"accessedAt":"2026-07-23","id":"source-1vr7uf8","canonicalPath":"/sources#source-1vr7uf8","peptides":[{"name":"Ipamorelin","slug":"ipamorelin"}]},{"label":"Randomized proof-of-concept study of ipamorelin for postoperative ileus","publisher":"PubMed · International Journal of Colorectal Disease","url":"https://pubmed.ncbi.nlm.nih.gov/25331030/","kind":"Randomized trial","year":2015,"accessedAt":"2026-07-23","id":"source-1p8ykgm","canonicalPath":"/sources#source-1p8ykgm","peptides":[{"name":"Ipamorelin","slug":"ipamorelin"}]},{"label":"VICTOZA (liraglutide) prescribing information","publisher":"U.S. Food and Drug Administration","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022341Orig1s043lbl.pdf","kind":"Drug label","year":2024,"accessedAt":"2026-07-23","id":"source-1wz9ia7","canonicalPath":"/sources#source-1wz9ia7","peptides":[{"name":"Liraglutide","slug":"liraglutide"}]},{"label":"SAXENDA (liraglutide) prescribing information","publisher":"U.S. Food and Drug Administration","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/206321s024lbl.pdf","kind":"Drug label","year":2026,"accessedAt":"2026-07-23","id":"source-1oju2xs","canonicalPath":"/sources#source-1oju2xs","peptides":[{"name":"Liraglutide","slug":"liraglutide"}]},{"label":"Liraglutide and cardiovascular outcomes in type 2 diabetes","publisher":"PubMed · New England Journal of Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27295427/","kind":"Randomized trial","year":2016,"accessedAt":"2026-07-23","id":"source-rbyxwt","canonicalPath":"/sources#source-rbyxwt","peptides":[{"name":"Liraglutide","slug":"liraglutide"}]},{"label":"LY3437943 in people with type 2 diabetes: a phase 1b randomized trial","publisher":"PubMed · The Lancet","url":"https://pubmed.ncbi.nlm.nih.gov/36354040/","kind":"Human pharmacology","year":2022,"accessedAt":"2026-07-23","id":"source-1751fdi","canonicalPath":"/sources#source-1751fdi","peptides":[{"name":"Retatrutide","slug":"retatrutide"}]},{"label":"Retatrutide for people with type 2 diabetes: a phase 2 randomized trial","publisher":"PubMed · The Lancet","url":"https://pubmed.ncbi.nlm.nih.gov/37385280/","kind":"Randomized trial","year":2023,"accessedAt":"2026-07-23","id":"source-1vq3ov","canonicalPath":"/sources#source-1vq3ov","peptides":[{"name":"Retatrutide","slug":"retatrutide"}]},{"label":"Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial","publisher":"PubMed · New England Journal of Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37366315/","kind":"Randomized trial","year":2023,"accessedAt":"2026-07-23","id":"source-1l4oq7r","canonicalPath":"/sources#source-1l4oq7r","peptides":[{"name":"Retatrutide","slug":"retatrutide"}]},{"label":"Retatrutide for metabolic dysfunction-associated steatotic liver disease","publisher":"PubMed · Nature Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38858523/","kind":"Randomized trial","year":2024,"accessedAt":"2026-07-23","id":"source-m9vp9x","canonicalPath":"/sources#source-m9vp9x","peptides":[{"name":"Retatrutide","slug":"retatrutide"}]},{"label":"TRIUMPH-1 phase 3 study record","publisher":"ClinicalTrials.gov","url":"https://clinicaltrials.gov/study/NCT05929066","kind":"Trial registry","year":2026,"accessedAt":"2026-07-23","id":"source-1tgbzft","canonicalPath":"/sources#source-1tgbzft","peptides":[{"name":"Retatrutide","slug":"retatrutide"}]},{"label":"TRIUMPH-2 phase 3 study record","publisher":"ClinicalTrials.gov","url":"https://clinicaltrials.gov/study/NCT05929079","kind":"Trial registry","year":2026,"accessedAt":"2026-07-23","id":"source-1uu6uep","canonicalPath":"/sources#source-1uu6uep","peptides":[{"name":"Retatrutide","slug":"retatrutide"}]},{"label":"TRIUMPH-3 phase 3 study record","publisher":"ClinicalTrials.gov","url":"https://clinicaltrials.gov/study/NCT05882045","kind":"Trial registry","year":2026,"accessedAt":"2026-07-23","id":"source-1gmce8a","canonicalPath":"/sources#source-1gmce8a","peptides":[{"name":"Retatrutide","slug":"retatrutide"}]},{"label":"TRIUMPH-1 topline results","publisher":"Eli Lilly and Company","url":"https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss","kind":"Reference","year":2026,"accessedAt":"2026-07-24","id":"source-rl6ji3","canonicalPath":"/sources#source-rl6ji3","peptides":[{"name":"Retatrutide","slug":"retatrutide"}]},{"label":"TRIUMPH-2 and TRIUMPH-3 topline results","publisher":"Eli Lilly and Company","url":"https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional","kind":"Reference","year":2026,"accessedAt":"2026-07-24","id":"source-ch5qie","canonicalPath":"/sources#source-ch5qie","peptides":[{"name":"Retatrutide","slug":"retatrutide"}]},{"label":"What to know about retatrutide","publisher":"Eli Lilly and Company","url":"https://www.lilly.com/news/stories/what-to-know-about-retatrutide","kind":"Regulatory","year":2026,"accessedAt":"2026-07-24","id":"source-1affe89","canonicalPath":"/sources#source-1affe89","peptides":[{"name":"Retatrutide","slug":"retatrutide"}]},{"label":"FDA concerns with unapproved GLP-1 drugs used for weight loss","publisher":"U.S. Food and Drug Administration","url":"https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss","kind":"Regulatory","year":2026,"accessedAt":"2026-07-24","id":"source-17dxao5","canonicalPath":"/sources#source-17dxao5","peptides":[{"name":"Retatrutide","slug":"retatrutide"}]},{"label":"EGRIFTA SV (tesamorelin) prescribing information","publisher":"U.S. Food and Drug Administration","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022505s018lbl.pdf","kind":"Drug label","year":2024,"accessedAt":"2026-07-23","id":"source-eanlgj","canonicalPath":"/sources#source-eanlgj","peptides":[{"name":"Tesamorelin","slug":"tesamorelin"}]},{"label":"EGRIFTA WR (tesamorelin) prescribing information","publisher":"U.S. Food and Drug Administration","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf","kind":"Drug label","year":2025,"accessedAt":"2026-07-23","id":"source-1myvnl1","canonicalPath":"/sources#source-1myvnl1","peptides":[{"name":"Tesamorelin","slug":"tesamorelin"}]},{"label":"Tesamorelin in HIV-associated abdominal fat accumulation","publisher":"PubMed · Journal of Acquired Immune Deficiency Syndromes","url":"https://pubmed.ncbi.nlm.nih.gov/20101189/","kind":"Randomized trial","year":2010,"accessedAt":"2026-07-23","id":"source-1vclb3b","canonicalPath":"/sources#source-1vclb3b","peptides":[{"name":"Tesamorelin","slug":"tesamorelin"}]},{"label":"Geref (sermorelin acetate) approval package","publisher":"U.S. Food and Drug Administration","url":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019863_S001_GEREF.pdf","kind":"FDA review","year":1991,"accessedAt":"2026-07-23","id":"source-7mjbji","canonicalPath":"/sources#source-7mjbji","peptides":[{"name":"Sermorelin","slug":"sermorelin"}]},{"label":"FDA determination that Geref was not withdrawn for safety or effectiveness","publisher":"Federal Register · U.S. Food and Drug Administration","url":"https://www.govinfo.gov/content/pkg/FR-2013-03-04/pdf/2013-04827.pdf","kind":"Regulatory","year":2013,"accessedAt":"2026-07-23","id":"source-1y7zgnx","canonicalPath":"/sources#source-1y7zgnx","peptides":[{"name":"Sermorelin","slug":"sermorelin"}]},{"label":"Sermorelin in diagnosis and treatment of pediatric growth hormone deficiency","publisher":"PubMed · BioDrugs","url":"https://pubmed.ncbi.nlm.nih.gov/18031173/","kind":"Science review","year":1997,"accessedAt":"2026-07-23","id":"source-1fj1b3x","canonicalPath":"/sources#source-1fj1b3x","peptides":[{"name":"Sermorelin","slug":"sermorelin"}]},{"label":"FDA briefing document for TB-500-related bulk drug substances","publisher":"U.S. Food and Drug Administration","url":"https://www.fda.gov/media/193349/download","kind":"FDA review","year":2026,"accessedAt":"2026-07-23","id":"source-k3rxw4","canonicalPath":"/sources#source-k3rxw4","peptides":[{"name":"TB-500","slug":"tb-500"}]},{"label":"TB-500 substance record","publisher":"U.S. Food and Drug Administration Global Substance Registration System","url":"https://precision.fda.gov/uniisearch/srs/unii/QHK6Z47GTG","kind":"Reference","year":2026,"accessedAt":"2026-07-23","id":"source-oq8mfk","canonicalPath":"/sources#source-oq8mfk","peptides":[{"name":"TB-500","slug":"tb-500"}]},{"label":"Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin","publisher":"PubMed · Archives of Facial Plastic Surgery","url":"https://pubmed.ncbi.nlm.nih.gov/16847171/","kind":"Randomized trial","year":2006,"accessedAt":"2026-07-23","id":"source-1uh9b0k","canonicalPath":"/sources#source-1uh9b0k","peptides":[{"name":"GHK-Cu","slug":"ghk-cu"}]},{"label":"503A bulk drug substances under evaluation","publisher":"U.S. Food and Drug Administration","url":"https://www.fda.gov/media/94155/download?attachment=","kind":"Regulatory","year":2026,"accessedAt":"2026-07-23","id":"source-1ui4fdo","canonicalPath":"/sources#source-1ui4fdo","peptides":[{"name":"GHK-Cu","slug":"ghk-cu"}]},{"label":"FDA briefing document for MOTS-c-related bulk drug substances","publisher":"U.S. Food and Drug Administration","url":"https://www.fda.gov/media/193347/download","kind":"FDA review","year":2026,"accessedAt":"2026-07-23","id":"source-xz8tt2","canonicalPath":"/sources#source-xz8tt2","peptides":[{"name":"MOTS-c","slug":"mots-c"}]},{"label":"MOTS-c substance record","publisher":"U.S. Food and Drug Administration Global Substance Registration System","url":"https://precision.fda.gov/uniisearch/srs/unii/A5CV6JFB78","kind":"Reference","year":2026,"accessedAt":"2026-07-23","id":"source-1sthg8h","canonicalPath":"/sources#source-1sthg8h","peptides":[{"name":"MOTS-c","slug":"mots-c"}]},{"label":"FDA briefing document for AOD-9604-related bulk drug substances","publisher":"U.S. Food and Drug Administration","url":"https://www.fda.gov/media/183584/download","kind":"FDA review","year":2024,"accessedAt":"2026-07-23","id":"source-ncn872","canonicalPath":"/sources#source-ncn872","peptides":[{"name":"AOD-9604","slug":"aod-9604"}]},{"label":"Sterile compounded AOD-9604 recall for lack of sterility assurance","publisher":"U.S. Food and Drug Administration","url":"https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/innoveix-pharmaceuticals-inc-issues-voluntary-recall-all-sterile-compounded-drug-products-due-lack-0","kind":"Regulatory","year":2021,"accessedAt":"2026-07-23","id":"source-11zmdqa","canonicalPath":"/sources#source-11zmdqa","peptides":[{"name":"AOD-9604","slug":"aod-9604"}]},{"label":"FDA briefing document for epitalon-related bulk drug substances","publisher":"U.S. Food and Drug Administration","url":"https://www.fda.gov/media/193345/download","kind":"FDA review","year":2026,"accessedAt":"2026-07-23","id":"source-5ny6o0","canonicalPath":"/sources#source-5ny6o0","peptides":[{"name":"Epitalon","slug":"epitalon"}]},{"label":"Epitalon and telomere length in human cell lines","publisher":"PubMed · Biogerontology","url":"https://pubmed.ncbi.nlm.nih.gov/40908429/","kind":"Preclinical","year":2025,"accessedAt":"2026-07-23","id":"source-ps7d39","canonicalPath":"/sources#source-ps7d39","peptides":[{"name":"Epitalon","slug":"epitalon"}]},{"label":"July 2026 Pharmacy Compounding Advisory Committee meeting","publisher":"U.S. Food and Drug Administration","url":"https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026","kind":"Regulatory","year":2026,"accessedAt":"2026-07-23","id":"source-w9soem","canonicalPath":"/sources#source-w9soem","peptides":[{"name":"Epitalon","slug":"epitalon"}]},{"label":"VYLEESI (bremelanotide) prescribing information","publisher":"U.S. Food and Drug Administration","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210557s002lbl.pdf","kind":"Drug label","year":2020,"accessedAt":"2026-07-23","id":"source-1vskwpk","canonicalPath":"/sources#source-1vskwpk","peptides":[{"name":"Bremelanotide","slug":"bremelanotide"}]},{"label":"Bremelanotide for HSDD: two randomized phase 3 trials","publisher":"PubMed · Obstetrics & Gynecology","url":"https://pubmed.ncbi.nlm.nih.gov/31599840/","kind":"Randomized trial","year":2019,"accessedAt":"2026-07-23","id":"source-bln3gw","canonicalPath":"/sources#source-bln3gw","peptides":[{"name":"Bremelanotide","slug":"bremelanotide"}]},{"label":"Vyleesi multidisciplinary review","publisher":"U.S. Food and Drug Administration","url":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210557Orig1s000MultidisciplineR.pdf","kind":"FDA review","year":2019,"accessedAt":"2026-07-23","id":"source-c62btw","canonicalPath":"/sources#source-c62btw","peptides":[{"name":"Bremelanotide","slug":"bremelanotide"}]},{"label":"SCENESSE (afamelanotide) prescribing information","publisher":"U.S. Food and Drug Administration","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210797s007lbl.pdf","kind":"Drug label","year":2024,"accessedAt":"2026-07-23","id":"source-k8r943","canonicalPath":"/sources#source-k8r943","peptides":[{"name":"Afamelanotide","slug":"afamelanotide"}]},{"label":"Afamelanotide for erythropoietic protoporphyria","publisher":"PubMed · New England Journal of Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26132941/","kind":"Randomized trial","year":2015,"accessedAt":"2026-07-23","id":"source-342qpf","canonicalPath":"/sources#source-342qpf","peptides":[{"name":"Afamelanotide","slug":"afamelanotide"}]},{"label":"Afamelanotide orphan drug designation and approval","publisher":"U.S. Food and Drug Administration","url":"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=263208","kind":"Regulatory","year":2019,"accessedAt":"2026-07-23","id":"source-1rygtu8","canonicalPath":"/sources#source-1rygtu8","peptides":[{"name":"Afamelanotide","slug":"afamelanotide"}]},{"label":"FORTEO (teriparatide) prescribing information","publisher":"U.S. Food and Drug Administration","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021318s057lbl.pdf","kind":"Drug label","year":2024,"accessedAt":"2026-07-23","id":"source-7a9tbx","canonicalPath":"/sources#source-7a9tbx","peptides":[{"name":"Teriparatide","slug":"teriparatide"}]},{"label":"Parathyroid hormone for postmenopausal osteoporosis","publisher":"PubMed · New England Journal of Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11248153/","kind":"Randomized trial","year":2001,"accessedAt":"2026-07-23","id":"source-1tizn38","canonicalPath":"/sources#source-1tizn38","peptides":[{"name":"Teriparatide","slug":"teriparatide"}]},{"label":"Teriparatide and femoral-neck fracture healing","publisher":"PubMed · Clinical Orthopaedics and Related Research","url":"https://pubmed.ncbi.nlm.nih.gov/26932738/","kind":"Randomized trial","year":2016,"accessedAt":"2026-07-23","id":"source-o88f3x","canonicalPath":"/sources#source-o88f3x","peptides":[{"name":"Teriparatide","slug":"teriparatide"}]},{"label":"TYMLOS (abaloparatide) prescribing information","publisher":"U.S. Food and Drug Administration","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208743Orig1s017lbl.pdf","kind":"Drug label","year":2025,"accessedAt":"2026-07-23","id":"source-sahy91","canonicalPath":"/sources#source-sahy91","peptides":[{"name":"Abaloparatide","slug":"abaloparatide"}]},{"label":"Abaloparatide vs placebo on new vertebral fractures: ACTIVE","publisher":"PubMed · JAMA","url":"https://pubmed.ncbi.nlm.nih.gov/27533157/","kind":"Randomized trial","year":2016,"accessedAt":"2026-07-23","id":"source-jgwcsw","canonicalPath":"/sources#source-jgwcsw","peptides":[{"name":"Abaloparatide","slug":"abaloparatide"}]},{"label":"GATTEX (teduglutide) prescribing information","publisher":"U.S. Food and Drug Administration","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/203441s024lbl.pdf","kind":"Drug label","year":2025,"accessedAt":"2026-07-23","id":"source-11pvwdv","canonicalPath":"/sources#source-11pvwdv","peptides":[{"name":"Teduglutide","slug":"teduglutide"}]},{"label":"Teduglutide reduces parenteral support in short bowel syndrome","publisher":"PubMed · Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/22982184/","kind":"Randomized trial","year":2012,"accessedAt":"2026-07-23","id":"source-p29dqt","canonicalPath":"/sources#source-p29dqt","peptides":[{"name":"Teduglutide","slug":"teduglutide"}]},{"label":"Teduglutide orphan drug designation and approval","publisher":"U.S. Food and Drug Administration","url":"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=126999","kind":"Regulatory","year":2019,"accessedAt":"2026-07-23","id":"source-mjypf1","canonicalPath":"/sources#source-mjypf1","peptides":[{"name":"Teduglutide","slug":"teduglutide"}]}]}